Stephen V Liu, MD· @StephenVLiu · X·· 21 小时前评分70
正文 · 机器翻译
#ESMO26 David Sommerhalder 医生介绍 M21-404 的 OS 数据：telisotuzumab adizutecan (Temab-A)，一种以 c-MET 为靶点、搭载 topo-1 载荷的 ADC。EGFR 野生型：mPFS 6.8个月，OS 13.8个月。EGFR 突变型：mPFS 10.9个月，OS 16.2个月。cMET 表达可预测 EGFRwt 患者的结局，但在 EGFRmt 中并非如此。
103 浏览 · 2 赞 · 0 转发 · 0 回复
会议摘要
2658RO按 Rapid oral 1: NSCLC, metastatic 对上
Overall survival (OS) analysis of telisotuzumab adizutecan in patients (pts) with nonsquamous non-small cell lung cancer (NSQ NSCLC): Phase 1 first-in-human study
https://esmocongress.esmo.org791RO按 Rapid oral: Gastrointestinal tumours, lower digestive 对上
Long-term follow-up of telisotuzumab adizutecan (ABBV-400, Temab-A) in combination with bevacizumab (Bev) vs standard of care (SOC) in patients (pts) with 3L+ colorectal cancer (CRC): Updated results of a phase 1 study
https://esmocongress.esmo.org来源：Stephen V Liu, MD · x.com